Abstract
In an effort to address the detrimental effects of myocardial ischemia/reperfusion injury (MI/RI), this study introduces a novel therapeutic strategy that involves a microneedle (MN) patch loaded with exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs) and carrying small interfering RNA (siRNA) targeting early growth response-1 (EGR1). By delivering hUCMSCs-derived exosomes containing EGR1 siRNA (hUCMSCs-Exosi-EGR1), the MN patch demonstrated promising cardioprotective effects in both in vitro and in vivo models of MI/RI. The results highlighted the efficacy of Exosi-EGR1 in enhancing cardiomyocyte viability, attenuating oxidative stress levels, and fostering mitophagy regulation. Moreover, the Exosi-EGR1 MN patch exhibited excellent mechanical properties and sustained drug release characteristics when embedded in a Gelatin methacryloyl (GelMA) matrix. Noteworthy outcomes from in vivo experiments included significant improvements in cardiac function, reduced cardiac fibrosis, and decreased apoptosis rates in MI/RI mice, emphasizing the potential therapeutic value of the Exosi-EGR1 MN patch in mitigating MI/RI through modulation of oxidative stress and mitophagy mechanisms.
Keywords: Myocardial ischemia/reperfusion injury, Exosomes, EGR1 siRNA, Microneedle patch, Oxidative stress
Graphical abstract
Protective effect of Exosomes MN Patch loaded with EGR1 siRNA on MI/RI through regulation of oxidative stress and promotion of mitophagy.
1. Introduction
Myocardial ischemia/reperfusion injury (MI/RI) is a pathological process commonly observed in various cardiovascular diseases, often resulting in severe myocardial damage and functional impairment [1,2]. This condition may trigger oxidative stress reactions during tissue ischemia and reperfusion, further exacerbating myocardial injury and resulting in cardiac dysfunction [3,4]. Despite the presence of some treatment methods, there is still a need to find more effective therapeutic strategies to improve patients' prognosis and quality of life [[5], [6], [7]].
Early Growth Response 1 (EGR1) is a key transcription factor involved in regulating cellular stress responses and autophagy, playing a critical role in myocardial injury [8]. Studies have shown that EGR1 is rapidly expressed after myocardial ischemia/reperfusion (MI/RI) and promotes the expression of genes related to inflammation and apoptosis, thus influencing disease states like MI/RI [8,9]. Silencing EGR1 in rat models of ischemia-reperfusion injury reduces myocardial inflammation and apoptosis, improving cardiac function, highlighting EGR1 as a potential therapeutic target for MI/RI [9]. Small interfering RNA (siRNA), a critical non-coding RNA, can silence specific genes through RNA interference. Research indicates that silencing EGR1 using siRNA can inhibit MI/RI-induced apoptosis, offering a novel approach to mitigating cardiac damage caused by MI/RI [10].
Exosomes are a type of cell-derived nanoparticles that play a crucial role in intercellular communication and interaction [11,12]. Rich in various bioactive molecules, including microRNA (miRNA), proteins, and mRNA, exosomes regulate cell function and gene expression [[13], [14], [15]]. Recent studies have demonstrated the potential of exosomes as carriers for delivering bioactive molecules in treating multiple diseases, including cardiovascular diseases [[16], [17], [18]].
Human umbilical cord mesenchymal stem cells (hUCMSCs) provide a widely available and easily obtainable source of stem cells with favorable biological characteristics and multipotent differentiation potential [19,20]. Exosomes derived from hUCMSCs-Exo are an important source of exosomes, characterized by high stability and drug delivery efficiency [21,22]. By employing electroporation technology, EGR1 siRNA can be successfully loaded into hUCMSCs-Exo, enabling targeted regulation of specific genes [23,24].
Due to the low retention rate of exosomes in myocardial tissue, direct injection of exosomes is generally ineffective for myocardial infarction treatment. To maintain therapeutic efficacy, repeated injections are required, which can lead to adverse side effects and increased treatment costs [25]. Microneedle (MN) patches represent a novel drug delivery system with excellent physical stability and drug release kinetics [26]. Given its biocompatibility, mechanical properties, and biodegradability, GelMA (Gelatin methacryloyl) was chosen as the MN material [25]. Loading hUCMSCs-Exo@si-EGR1 into the GelMA matrix to create MN patches enables sustained and controlled drug release [[27], [28], [29]]. These MN patches can deliver drugs to target tissues through skin penetration and achieve prolonged therapeutic effects via continuous drug release [[30], [31], [32]].
This study aims to investigate the protective effects of the hUCMSCs-Exosi-EGR1 MN patch loaded with EGR1 siRNA on oxidative stress and mitophagy regulation in an MI/RI model. By modulating oxidative stress and promoting mitophagy mechanisms, this MN patch significantly reduces myocardial injury caused by MI/RI and improves cardiac function. This strategy holds significant clinical significance and offers a promising new and effective treatment approach for MI/RI. Further research will help enhance our understanding of the mechanisms involved in this treatment strategy, providing more comprehensive scientific evidence for its clinical application.
2. Materials and methods
2.1. Identification and culture of hUCMSCs
HUCMSCs were purchased from Shandong Qilu Cell Therapy Engineering Technology. The cells were cultured in Dulbecco's modified eagle medium (DMEM, 11965092) containing 1 % glutamine, 10 % fetal bovine serum (FBS, 10099141C), and 100 μg/mL of streptomycin and penicillin. The reagents were obtained from ThermoFisher. The cell culture was maintained at 37 °C with 5 % CO2 in a CO2 incubator. After three passages, hUCMSCs were characterized using flow cytometry. Phycoerythrin (PE)-conjugated antibodies CD105 (ab272352, 1:100), CD73 (ab282789, 1:50), CD90 (ab95698, 1:100), CD45 (ab269297, 1:50), CD34 (ab187284, 1:50), CD14 (ab91143, 1:200), CD19 (ab269320, 1:50), and HLA-DR (ab64676, 1:50) purchased from Abcam (UK) were used for labeling. Subsequently, samples were analyzed using the FACSVerse instrument (BD Bioscience), and the results were analyzed with FlowJo software (Tree Star, Ashland, OR, USA) [33].
To assess the differentiation potential of hUCMSCs, cells were cultured in OriCell™ MSC osteogenic medium (HUXUC-90021), adipogenic medium (catalog number: HUXUC-90031), or chondrogenic medium (HUXUC-90041). Identification was performed using Alizarin Red, Oil Red O, and Alcian Blue staining [25,34].
2.2. Separation and characterization of hUCMSCs-Exo
HUCMSCs were cultured for 48 h in DMEM/F12 medium (12634010, Gibco) containing 10 % exosome-free fetal bovine serum (EXO-FBS-50A-1; Systembio) and 1 % penicillin-streptomycin (15140148, Gibco). The supernatant was collected and centrifuged at 300 g for 10 min and then at 12,000 g for 1 h at 4 °C. The resulting supernatant was filtered through a 0.22 μm membrane to remove cells and cell debris, and the filtered supernatant was then ultracentrifuged at 110,000 g for 2 h. The resulting pellet was carefully resuspended in phosphate buffer saline(PBS) for immediate use or storage at −80 °C.
The morphology, size, surface charge, and protein expression of the exosomes were characterized using transmission electron microscopy (TEM), dynamic light scattering (DLS), electrophoretic light scattering (ELS), and Western blot analysis. For TEM, exosomes were resuspended in PBS at a final 500 μg/mL concentration and fixed with 2.5 % glutaraldehyde solution for 2 h at room temperature. Then, 20 μL of the exosome solution was placed on a copper grid and stained with 1 % phosphotungstic acid (pH 6.0) for 5 min. Images were captured using a transmission electron microscope (Talos F200X S/TEM; Thermo Fisher Scientific).
The size and zeta potential of the exosomes were measured using a Zetasizer Nano ZS instrument (Malvern Instruments, UK). The exosomes were appropriately diluted in PBS (pH 7.0) at 25 °C. The average hydrodynamic diameter and zeta potential were determined by ELS, and the Zeta potential results were reported as the mean ± standard deviation.
For Western blot analysis, exosomes were dissolved in radioimmunoprecipitation assay (RIPA) buffer, and their quantification was performed using the BCA protein assay kit (A53226, Thermo Fisher Scientific, USA). The expression of exosomal marker proteins CD63 (ab216130, 1:1000), HSP70 (ab2787, 1:1000), and endoplasmic reticulum marker protein Calnexin (ab22595, 1:1000) was detected using Western blot [25]. Antibodies were purchased from Abcam (UK), and the experiment was repeated three times.
2.3. Loading of EGR1 siRNA into hUCMSCs-Exo by electroporation
Isolated exosomes were resuspended in an electroporation buffer to a final concentration of 1 μg/μL 500 pmol of EGR1 siRNA was added to the resuspended exosomes solution. For visualization of transfection efficiency, the siRNA was pre-labeled with Dil fluorescent dye. The exosomes mixture containing EGR1 siRNA (reverse strand: 5′-CCUUCUCCAGCUGCUUCAUCGUCUU-3′, forward strand: 5′-AAGACGAUGAAGCAGCUGGAGAAGG-3′) was aspirated into Amaxa electroporation cuvette and electroporated using the LONZA Nucleofector 4D system. The electroporation parameters were set to 0.35 s pulse, 20 times, and a voltage of 0.7 kV. After electroporation, RNase A treatment was immediately conducted for 30 min to degrade any free siRNA. Subsequently, 2 μL of RNase inhibitor (HY-K1033, MedChemExpress, USA) was added to stop the activity of RNase A. The processed exosomes were re-separated through the aforementioned ultracentrifugation steps, and the resulting pellet was resuspended in PBS. After loading Dil-labeled EGR1 siRNA into hUCMSCs-Exo by electroporation, the mixture was incubated with immunomagnetic beads conjugated with CD63 antibody at 37 °C for 30 min. Fluorescence microscopy (Olympus IX71, Tokyo, Japan) was used to analyze the fluorescence signal to confirm the successful loading of EGR1 siRNA.
To assess the serum stability of the siRNA delivery system, free EGR1 siRNA or hUCMSCs-Exosi-EGR1 were co-incubated with 50 % FBS for 24 h. Gel electrophoresis was performed at 0, 1, 2, 4, 8, 12, 16, 20, and 24 h, and siRNA degradation was observed under an ultraviolet illumination [35].
2.4. In vitro cytotoxicity assay
Cell viability was assessed using the CCK-8 method. Cells were co-cultured with hUCMSCs-Exosi-EGR1 or hUCMSCs-Exo at different concentrations (0, 100, 200, 300, 400, and 500 μg/mL). After 24 h of treatment, cell viability was evaluated by adding 10 μL of CCK-8 reagent (C0037, Biyun Tian Biological Technology Co., Ltd.) to each wel. Absorbance at 450 nm was measured using an enzyme-linked immunosorbent assay (ELISA) reader to evaluate changes in cell viability [35].
2.5. Identification, isolation, and cultivation of primary mouse cardiomyocytes
C57BL/6J mice (strain code: 219, Beijing Vito Li Hua Animal Experiment Co., Ltd.) were euthanized by cervical dislocation, and the hearts were collected for dissection to obtain ventricular muscle tissue. Tissue digestion was performed using 0.2 % trypsin to isolate single cardiomyocyte suspension. The cells isolated were cultured at 37 °C and 5 % CO2 in DMEM culture medium containing 10 % fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cardiomyocyte purity was evaluated using cTnI immunofluorescence staining, with a purity above 95 % considered successful isolation (Fig. S1).
For immunofluorescence staining, the cells were plated in immunofluorescence chambers at a density of 2 × 10^5 cells per well. Once the cell confluence reached approximately 90 %, cells were washed three times with PBS (on ice), fixed with 4 % paraformaldehyde (1 mL per well) for 15 min at room temperature, and then permeabilized with 0.2 % Triton X-100. After three washes with PBS, the cells were blocked with 5 % BSA for 30 min and incubated overnight at 4 °C with an anti-cardiac troponin I antibody (ab47003, 1:400, Abcam, UK). After three washes with PBS, cells were incubated with goat anti-rabbit IgG H&L (FITC) secondary antibody (ab6717, 1:1000, Abcam, UK) for 1 h at room temperature, protected from light. After three washes with PBS, cells were stained with DAPI (C1002, Beyotime, Shanghai, China) for 15 min, followed by three PBS washes in the dark. Fluorescence quenching agent was applied for mounting, and observation was performed under a fluorescence microscope (Olympus, Japan) [36].
2.6. Cellular internalization of exosomes
Dil-labeled hUCMSCs-Exo were suspended in the basal culture medium at a concentration of 10 μg/mL and co-incubated with primary mouse cardiomyocytes. The cells were then fixed using 4 % paraformaldehyde and stained with 1 % DAPI solution (62248, Thermo Scientific, USA) for nuclear visualization, which was performed for 10 min. The cellular uptake of hUCMSCs-Exo was observed using confocal laser scanning microscopy (Zeiss LSM710, Germany) [37].
2.7. In vitro simulation of MI/RI
To mimic MI/RI, primary mouse cardiomyocytes were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) treatment. Specifically, the cells were cultured in glucose-free DMEM medium until they reached approximately 70 % confluency and then incubated in a tri-gas incubator (Thermo Fisher Scientific) containing 95 % nitrogen and 5 % CO2. After 3 h of OGD treatment, the cells were cultured in the glucose-containing medium for 0, 2, 4, 6, and 8 h [38].
Cell Groups: The following groups were established: Control group (primary mouse cardiomyocytes cultured under normal conditions), OGD/R group (cells subjected to 3 h of OGD treatment followed by 4 h of reoxygenation), OGD/R + hUCMSCs-Exo group (cells subjected to 3 h of OGD treatment followed by 4 h of reoxygenation, pre-treated with 10 μg/mL of hUCMSCs-Exo), OGD/R + Exosi-EGR1 group (cells subjected to 3 h of OGD treatment followed by 4 h of reoxygenation, pre-treated with 10 μg/mL of Exosi-EGR1).
3. Measurement of ROS content
A reactive oxygen species (ROS) assay kit (Catalog number: S0033M, Beyotime, Shanghai, China) was used to detect ROS levels. A 10 μM solution of dichlorofluorescein diacetate (DCFH-DA) was prepared in a serum-free culture medium as directed in the kit manual. The cells under examination were suspended in the DCFH-DA solution and incubated at 37 °C for 20 min. The mixture was inverted every 3–5 min to ensure ample probe-cell contact. The cells were then washed three times with a serum-free cell culture medium to remove any unabsorbed DCFH-DA completely. The ROS levels of each cell group were measured using flow cytometry (FACSVerse, BD, USA) [39].
3.1. ELISA
The Malondialdehyde (MDA) Kit (E-EL-0060) and Total Superoxide Dismutase (T-SOD) Activity Assay Kit (WST-1 Method) (E-BC-K020-M) were used to measure the MDA and SOD content in the cell supernatant. The specific steps were followed according to the instructions provided with the respective kits, which were purchased from Wuhan Elabscience Biotechnology Co., Ltd [38].
3.2. JC-1 measurement of mitochondrial membrane potential
The mitochondrial membrane potential was measured using a mitochondrial membrane potential assay kit containing JC-1 (Catalog number: C2003S, Beyotime, Shanghai, China). Cells were digested with trypsin and suspended in 0.5 mL of culture medium. The JC-1 staining solution was added, and the samples were mixed by inverting several times. The cells were then incubated at 37 °C for 20 min. After incubation, the cells were centrifuged at 600 g for 4 min to collect a pellet. The pellet was washed twice with JC-1 staining buffer, and mitochondrial membrane potential was assessed by flow cytometry (FACSVerse, BD, USA) [40].
3.3. Transmission electron microscopy (TEM) observation
After OGD/R treatment, cells were harvested and fixed in a 2 % paraformaldehyde solution. The fixed cells were then washed with PBS and embedded in resin for sectioning. Ultrathin sections (50–70 nm) were prepared using the Leica Biosystems EM UC6 ultramicrotome. Subsequently, the sections were stained with uranium and lead for double staining. The samples were observed and imaged using the Hitachi TEM system (HT7800) from Hitachi Inc [41].
For tissue sections, the slices were immersed in a 1 % uranyl acetate solution for 5 min, followed by incubation in a CO2-free environment for 2–4 min to produce citrate salts. The sections were then examined using the Hitachi H7650 transmission electron microscope at 100 kV, and images were captured digitally using the AMT V700 side-mounted camera to visualize autophagosomes [42].
3.4. Fluorescent staining of mitophagy
Cells were transfected with a specific GFP-LC3 lentivirus provided by Genechem Inc. (China) following the manufacturer's protocol. A suitable multiplicity of infection (MOI) of up to 50 viral particles was chosen for infection. After 72 h, cells were selected with 5 μg/ml puromycin (USA) to isolate positive cells. After 48 h of selection, mitochondria were stained with Mito-tracker Red (C1032) provided by Beyotime Inc. (China), and the colocalization of mitochondria with autophagosomes was observed using fluorescence microscopy. The fluorescent images of cells were observed and captured using a fluorescence microscope from Olympus Inc. (Japan), and the colocalization of mitochondria with GFP-LC3-labeled autophagosomes was recorded and statistically analyzed using ImageJ software [43].
3.5. TUNEL staining for apoptosis detection
Cells were fixed with 4 % paraformaldehyde at room temperature for 15 min and then permeabilized with 0.25 % Triton X-100 at room temperature for 20 min. Cells were cultured in 5 % bovine serum albumin (Yeasen Biotech Co., Ltd.) before staining with the TUNEL reagent (C1086, Beyotime, Shanghai, China). Tissue sections were counterstained with DAPI (62248, Thermo Scientific, USA) in the dark. Fluorescence microscopy was used to capture images of apoptotic cells. ImageJ software was employed to identify and count TUNEL-positive cells, and the positivity rate was calculated [38].
For tissue apoptosis analysis, the TUNEL assay was performed according to the manufacturer's instructions (11684795910, Roche, USA). Briefly, tissue sections were deparaffinized and rehydrated, followed by treatment with proteinase K and 3 % hydrogen peroxide. The sections were incubated with the TUNEL reaction mixture in a humid chamber at 37 °C, labeled with fluorescein-dUTP, and counterstained with hematoxylin. Fluorescence microscopy (Zeiss Observer Z1, Germany) was used to observe the sections, and ImageJ software was used to analyze and count TUNEL-positive cells and calculate the positivity rate [44].
3.6. Reverse transcription-polymerase chain reaction (RT-qPCR)
RNA was extracted from both tissues and cells using Trizol (Thermo Fisher Scientific, USA, Catalog No. 16096020), and RNA concentration and purity were measured using a NanoDrop One/OneC spectrophotometer (Thermo Scientific). The A260/A280 ratio was verified to be 2.0, and RNA concentration was greater than 5 μg/μL. Reverse transcription was performed using the cDNA First Strand Synthesis Kit (Shanghai Beyotime, Catalog No. D7168L).
The RT-qPCR experiment was conducted according to the instructions provided with the RT-qPCR Kit (Vazyme Biotech, Nanjing, Catalog No. Q511-02). Briefly, 2 μL of cDNA template was mixed with 0.2 μL of each upstream and downstream primer, 10 μL of RT-qPCR Mix, and RNAase-free water was added to a total volume of 20 μL. The PCR amplification was performed on a Bio-Rad real-time quantitative PCR instrument CFX96, with the following cycling conditions: initial denaturation at 95 °C for 30 s, denaturation at 95 °C for 10 s, annealing at 60 °C for 30 s, elongation at 72 °C for 30 s, for a total of 40 cycles. The melt curve analysis was performed from 65 °C to 95 °C. The primer sequences were designed and provided by Shanghai Bioengineering Co., Ltd, and the specific sequences are listed in Table S1 β-actin was used as the reference gene, and the fold change of target gene expression in the experimental group compared to the control group was calculated using the 2−ΔΔCt method. The formula used was ΔΔCt = ΔCt experimental group - ΔCt control group, where ΔCt = Ct (target gene) - Ct (reference gene) [45]. The experiment was repeated three times.
3.7. Western blot analysis for protein expression
The tissue and cell samples were lysed using RIPA lysis buffer (P0013B, Beyotime, Shanghai) containing 1 % phenylmethanesulfonyl fluoride (PMSF) to extract total proteins. Mitochondria and cytoplasmic proteins were separated using the Mitochondria Isolation Kit (Catalog No. C3601, Beyotime, Shanghai, China). The total protein concentration of each sample was determined using the BCA assay kit (P0011, Beyotime, Shanghai). An 8%–12 % SDS gel was prepared based on the size of the target protein bands, and protein samples were loaded into each lane using a micropipette for electrophoresis. The proteins on the gel were then transferred to a PVDF membrane (1620177, BIO-RAD, USA) and incubated at room temperature for 1 h in 5 % non-fat milk for blocking. Antibodies, including rabbit anti-Cytochrome C (CytC) (ab133504, 1:2000, Abcam), rabbit anti-Bax (ab32503, 1:1000, Abcam), rabbit anti-Bcl2 (ab196495, 1:1000, Abcam), rabbit anti-LC3B (ab192890, 1:2000, Abcam), rabbit anti-p62 (ab109012, 1:2000, Abcam), rabbit anti-cleaved-caspase3 (ab231289, 1:1000, Abcam), and mouse anti-β actin (ab8226, 1:5000, Abcam), were added and incubated overnight at 4 °C. The membrane was washed 3 times for 5 min each with 1 × TBST at room temperature. Goat anti-rabbit IgG-HRP (ab6721, 1:2000) or goat anti-mouse IgG-HRP (ab6728, 1:2000), purchased from Abcam, was added and incubated at room temperature for 1 h. The membrane was then washed 3 times for 5 min each with 1 × TBST at room temperature. Band exposures were performed using an Image Quant LAS 4000C gel imaging system (GE, USA) with ECL reagent (1705062, Bio-Rad, USA). The relative expression levels of the target proteins were determined by measuring the ratio of the target band's intensity to the intensity of the internal reference β-actin band. Protein expression levels were analyzed using beta-actin as the internal control [46]. Each experiment was repeated three times.
3.8. Preparation of GelMA hydrogel
GelMA hydrogel is synthesized by methacrylation of gelatin. Firstly, 10 g of gelatin (Sigma-Aldrich, 73865) is added to a 100 mL PBS solution and stirred continuously at 60 °C until fully dissolved. Next, methacrylic anhydride (Sigma-Aldrich, 276685) is slowly added dropwise to the gelatin solution in 10 mL increments, and the mixture is heated and stirred at 60 °C for 2 h. Then, preheated PBS buffer (60 °C) is added and stirring is continued for 1–2 h. Subsequently, the obtained solution is poured into a dialysis bag and dialyzed at 60 °C for 7 days to remove excess methacrylic anhydride. Finally, GelMA is obtained by freeze-drying and stored at −20 °C for later use [47].
3.9. Preparation of GelMA MN patch loaded with hUCMSCs-Exo
Following the previously described GelMA preparation method, GelMA is dissolved in PBS and adjusted to a concentration of 30 % (w/v). An appropriate volume of 1 % photoinitiator (2-hydroxy-2-methylpropiophenone) is added. The solution is then dropped into a negative PDMS mold (consisting of 385 cone-shaped arrays with a diameter of 17.5 mm, cone length of 570 μm, and base diameter of 260 μm). The air inside the cone-shaped MN cavities is removed by centrifugation, and the mixed solution is filled into the cavities. The composite prepolymer MN solution is cured using ultraviolet light (365 nm). The dry GelMA MN patch is immersed in a solution containing 50 μg/mL of hUCMSCs-Exo or hUCMSCs-Exosi-EGR1 for 12 h. After immersion, the MN patch is removed from the solution, any residual liquid on the surface is gently absorbed using blotting paper, and then the remaining solution is removed by freeze-drying [47].
3.10. Adhesion test of isolated mouse cardiac tissue
The tissue adhesion strength of the MN patch was evaluated using the Instron 5542 mechanical testing machine [48]. LV tissues from mouse hearts were used as the substrate. Hearts were cleaned to remove blood vessels and atria, and the ventricles were sectioned into 1 × 1 cm fragments and immersed in Dulbecco's phosphate-buffered saline (DPBS). Tissue samples were adhered to glass slides using cyanoacrylate glue. Two substrate parts were positioned facing each other, and the MN patch was photocrosslinked to the tissue for 300 s. Samples (n = 6) were stretched at a rate of 1 mm/min, and the maximum adhesive strength at the point of patch failure was measured [49].
3.11. Mechanical performance of the MN patch
The GelMA MN patch (with the tip facing upwards) is placed on a fixed platform of a Microelectromechanical Systems (MEMS) analyzer. The force sensor is carefully positioned towards the MN patch until it makes contact with the tip of the MN. Once contact is established, the force sensor moves towards the MN patch at a constant speed of 0.2 mm/s until a displacement of 0.4 mm is reached [47].
3.12. EGR1 siRNA release profile
Since siRNA is pre-labeled with Dil fluorescence, the release of siRNA is observed by measuring the fluorescence intensity. The GelMA MN patch loaded with hUCMSCs-Exo is fully immersed in PBS solution at room temperature. Over the next 12 h, specific amounts of the PBS solution are withdrawn every hour, and the fluorescence intensity is measured using a fluorescence microscope. After each sampling, an equal volume of fresh PBS solution is added to the experimental container to maintain a constant total volume, simulating a continuous physiological environment. Within the following 15 days, the fluorescence intensity of the solution is measured every other day to track the long-term release behavior of EGR1 siRNA. The fluorescence intensity data from each measurement is recorded, and a release curve of EGR1 siRNA is plotted [47].
Prepared MN patches loaded with EGR1 siRNA were tested for in vitro release. Equipment included dialysis bags (with a molecular weight cutoff matching siRNA size), a constant temperature shaker, and an ultraviolet spectrophotometer. Briefly, MN patches loaded with EGR1 siRNA and blank MN patches were placed into separate dialysis bags containing a release medium, such as PBS. After sealing, the dialysis bags were immersed in containers with fresh release medium and incubated at 37 °C on a shaker at a consistent speed (e.g., 100 rpm). At predetermined intervals (e.g., 1, 2, 4, 6, 8, 12, and 24 h), aliquots of the release medium were collected and replaced with an equal volume of fresh medium. The EGR1 siRNA content in the collected medium was quantified using an ultraviolet spectrophotometer, and the cumulative release was calculated based on a standard curve. A release profile of EGR1 siRNA from the MN patch was plotted, and comparative analysis determined the efficacy and kinetics of EGR1 siRNA release.
3.13. Mouse myocardial ischemia/reperfusion model
Male C57BL/6J mice, aged 8–10 weeks (strain code: 219, Beijing Weitonglihua Animal Experiment Co., Ltd.), were used to establish the mouse MI/RI model. As previously described [50], mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and then intubated. The left thoracic cavity of the mouse was incised, and the left anterior descending artery (LAD) was operated on, guided from the left atrium to the anterior wall of the left ventricle. Myocardial ischemia was induced by loosely tying a 6/0 circular needle suture. Regional pale myocardium in the left ventricle and elevation of the ST segment in the electrocardiogram were indicators of successful myocardial ischemia. After 30 min of ischemic induction, the suture was released to allow reperfusion in the mouse for 60 min. For the MN patch treatment, the patch was fixed to the ischemic area of the myocardium 5 min after ligation, and ischemic induction continued for 30 min before releasing the ligation and conducting a 60-min reperfusion. Subsequently, the thoracic cavity was sutured, the tracheal tube was removed, and the mice were allowed to regain spontaneous breathing. Sham-operated mice underwent the same procedures as the model mice, except for LAD ligation. All procedures were performed under sterile conditions [51]. The success of myocardial infarction was confirmed by regional pallor below the suture site and subsequent echocardiographic evaluation. In the OGD/R + hUCMSCs-Exo and OGD/R + Exo@si-EGR1 groups, MN patches were applied to the epicardial surface of the infarcted and peri-infarcted regions 10 days after myocardial infarction when the scar had matured [47]. The si-EGR1 used in this study was custom-synthesized with fluorescent labeling by a commercial provider.
3.14. Measurement of cardiac function
Cardiac function measurement was performed using the Vevo 3100 high-frequency micro-ultrasound imaging system (VisualSonics, Canada) equipped with a 70 MHz transducer, and data were analyzed using Vevo Lab v3.2.0 software (VisualSonics, Canada). Before the experiment, mice were anesthetized with isoflurane gas and properly positioned on a specialized board to ensure stability throughout the examination. The heart was imaged in 2D and M modes, particularly at 3, 7, 14, and 28 days post-ischemia/reperfusion. Parasternal short-axis views at the papillary muscle level were obtained using M-mode two-dimensional echocardiography (Ultrasonic Cardiogram, UCG) to measure left ventricular (LV) wall thickness, left ventricular end-diastolic dimension (LVEDD), and left ventricular end-systolic diameter (LVESD).
Additionally, left ventricular end-diastolic diameter (LVID'd), left ventricular end-systolic diameter (LVID's), interventricular septum thickness (IVS), and left ventricular posterior wall thickness (LVPW) were observed. Left ventricular fractional shortening (FS%) and ejection fraction (EF%) were calculated using formulas to assess cardiac function [51].
3.15. Histological analysis
On the 28th day post-reperfusion, mice were euthanized. Before fixation, all hearts were placed in a cardioplegic solution to ensure relaxation. The hearts were fixed in a 4 % formaldehyde solution for 7 days for histological analysis. Subsequently, dehydrated tissues were embedded in paraffin and cut into 5 μm sections. The paraffin sections were then subjected to immunohistochemical staining, Masson's-trichrome staining, hematoxylin and eosin (H&E) staining, Sirius-red (SR) staining (Solarbio), and c-TNC immunofluorescence staining.
Masson's staining: De-waxed and dehydrated sections were placed in water for 30 min, followed by immersion in Weigert's iron hematoxylin staining for 5–10 min. Acid alcohol differentiation, water washing, and counterstaining with Masson's blue solution were performed to restore the blue color. Then, the sections were stained with ponceau fuchsin solution for 5–10 min, washed with phosphomolybdic acid solution for 5–10 min, and stained with aniline blue solution for 1–2 min. After a 1-min wash with a weak acid solution, the sections were dehydrated rapidly in 95 % ethanol three times, cleared in xylene three times (1–2 min each), and then mounted with neutral balsam. ImageJ software was used to differentiate the different stained areas based on color thresholding and calculate the percentage or area of each color region [52].
H&E staining: The prepared sections were stained with hematoxylin solution (H8070, Solarbio, Beijing, China) for 5–10 min at room temperature. After rinsing with distilled water, the sections were placed in an eosin staining solution (G1100, Solarbio, Beijing, China) for 5–10 min, followed by routine dehydration, clearing, and mounting [53].
Sirius-red staining: The prepared sections were stained with a Sirius-red solution (G1473, Solarbio, Beijing, China) for 30 min, washed with water, dehydrated with an alcohol series, cleared with xylene, and then mounted. ImageJ software was used to differentiate the area stained with Sirius-red and calculate the percentage or area of the stained region [54].
Immunohistochemical staining: The sections were subjected to antigen retrieval by heating in a citrate buffer, followed by blocking endogenous peroxidase using 3 % hydrogen peroxide and blocking nonspecific binding sites using a blocking solution. The sections were then incubated with the primary antibodies against 8-OHdG (ab48508, 1:200, Abcam, UK) or EGR1 (ab300449, 1:500, Abcam, UK) overnight at 4 °C, followed by incubation with goat anti-mouse IgG H&L (HRP) (ab205719, 1:2000, Abcam, UK) at room temperature for 1 h. DAB chromogen (ab64238, Abcam, UK) was used for visualization, followed by counterstaining with hematoxylin. After dehydration, clearing, and mounting with xylene, the sections were subjected to image analysis using ImageJ software to identify and count 8-OHdG-positive cells and EGR1-positive cells and calculate the positivity rate [55].
c-TNC immunofluorescence staining: The sections were incubated with Anti-Tenascin C antibody (ab215369, 1:200, Abcam, UK) overnight at 4 °C. After washing three times with PBS for 5–10 min each, the sections were incubated with goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077, 1:500, Abcam, UK) at room temperature in the dark for 1–2 h. After three washes with PBS, the sections were stained with DAPI (C1002, Beyotime, Shanghai, China) in the dark for 15 min, followed by three washes with PBS in the dark. Finally, the sections were mounted with a fluorescence quencher. The expression of Dil and TNC were observed and photographed under a fluorescence microscope (Olympus, Japan).
3.16. Evaluation of tissue-targeting effects of MN patches in a myocardial ischemia/reperfusion model
A mouse MI/RI model was used, with mice randomly assigned to three groups: the first group received MN patches loaded with EGR1 siRNA applied to the heart; the second group served as the negative control (MN patches loaded with non-targeting siRNA applied to the skin over the heart); and the third group served as the blank control (similar skin treatment without MN patch application). Heart tissue samples were collected at various time points after MN patch treatment (e.g., 24 h, 48 h, 72 h). Part of the tissue was used for RNA extraction using an RNA extraction kit, followed by reverse transcription to obtain cDNA. The expression level of EGR1 mRNA was assessed by real-time quantitative PCR to determine whether the EGR1 siRNA-loaded MN patch specifically reduced EGR1 transcription at the tissue level.
3.17. Investigation of MN patch-mediated targeting of intracellular EGR1 expression
The remaining tissue was used for isolating single cells using a cell separation solution. For non-fluorescently labeled cells, immunofluorescence staining combined with laser confocal microscopy was used for observation. After fixing the isolated cells and blocking free antibody binding sites with Rabbit (DA1E) mAb IgG Xp® Isotype Control #3900, cells were labeled with AQP4 (D1F8E) XP® Rabbit mAb (Alexa Fluor® 488 Conjugate) #82941 (green) and stained with DAPI for nuclear visualization. The samples were mounted in ProLong® Gold anti-fade reagent containing DAPI #8961 (blue). The cells were then observed using a confocal microscope to assess the localization of EGR1 protein in relation to the nucleus and to evaluate the strength of EGR1 fluorescence signals in cells from different groups, thus determining the targeting effect of the MN patch on EGR1.
3.18. Subcellular targeting effects of MN patches: analysis of EGR1 localization and structural changes
Next, the isolated cells were processed using a subcellular protein separation kit (Thermo, Catalog Nos. 78840, 87790) to separate specific organelles. The first kit reagent selectively permeabilized membranes, releasing soluble cytoplasmic contents. The second reagent dissolved plasma, mitochondrial, and ER-Golgi membranes but not nuclear membranes. After centrifugally recovering intact nuclei, the third reagent was used to extract soluble nuclear extracts. An additional extraction step was carried out using micrococcal nuclease to release chromatin-bound nuclear proteins. The final reagent was used to extract and recover insoluble chunks for separating cytoskeletal proteins. The amount of EGR1 protein in the separated organelles was assessed by Western blot (sc-515830), with organelle-specific marker proteins used as internal controls. Differences in EGR1 protein expression across the groups were compared to confirm whether EGR1 siRNA specifically targeted the organelles.
Furthermore, the isolated cells were fixed, dehydrated, and embedded for ultrathin sectioning. Transmission electron microscopy (TEM) was then used to observe the ultrastructure of organelles and any structural changes associated with EGR1 siRNA. This analysis at the ultrastructural level further validated the MN patch's targeting effect on the subcellular level.
3.19. Statistical analysis
The data were obtained from at least three independent experiments and presented as mean ± standard deviation (Mean ± SD) for continuous variables. Statistical analysis of the data was performed using one of two methods: a two-tailed, unpaired Student's t-test or a one-way analysis of variance (ANOVA), followed by Tukey's multiple comparison test to determine differences between groups at individual time points. For the determination of differences between groups at multiple time points, a two-way ANOVA was used, followed by Bonferroni's multiple comparison test. All analyses were conducted using Prism 8 software (GraphPad), and statistical significance was considered when the p-value was less than 0.05.
4. Results
4.1. Isolation and characterization of hUCMSCs-Exo
In recent years, the role of exosomes derived from hUCMSCs in MI/RI has been widely reported [[56], [57], [58]]. First, we identified hUCMSCs using optical microscopy. We observed that hUCMSCs exhibited a slender or spindle-shaped morphology, arranged in a swirling pattern, and demonstrated differentiation potential into bone, fat, and cartilage (Figs. S2A–B). Flow cytometry results revealed that hUCMSCs expressed CD90, CD105, and CD73 while not expressing CD45, CD34, CD14, CD19, and HLA-DR, consistent with the phenotype of mesenchymal stem cells (Fig. S2C). Additionally, we isolated exosomes derived from hUCMSCs (hUCMSCs-Exo). TEM, DLS, and Western blot confirmed that the isolated hUCMSCs-Exo possessed a bilayer membrane structure, exhibited saucer-like morphology, and had diameters ranging from 30 to 100 nm. Furthermore, hUCMSCs-Exo showed high expression of CD63 and HSP70 and no expression of Calnexin (Figs. S2D–F). These results indicate the successful isolation and identification of hUCMSCs-Exo.
4.2. Evaluation of in vivo stability and delivery efficiency of si-EGR1 loaded in hUCMSCs-Exo
Previous studies have indicated that silencing EGR1 facilitates the autophagy process in cardiomyocytes of MI/RI mice, thus effectively improving myocardial damage [50]. Building upon this finding, this study successfully loaded siRNA targeting EGR1 (si-EGR1) into hUCMSCs-Exo using electroporation technology, resulting in the preparation of exosomes with potential therapeutic effects (Exosi-EGR1).
In order to ensure effective cargo loading of si-EGR1, immunomagnetic bead capture technology was employed, and si-EGR1 was tracked using Dil labeling. Fluorescence microscopy observations revealed strong Dil fluorescence, indicating the successful introduction of si-EGR1-Dil into hUCMSCs-Exo (Fig. 1A). Additionally, TEM images clearly displayed the discoid morphology of hUCMSCs-Exosi-EGR1, demonstrating that si-EGR1 loading did not affect the shape of the exosomes (Fig. 1B). DLS analysis of size distribution revealed average diameters of 98 ± 2.1 nm for hUCMSCs-Exo and 108 ± 2.6 nm for Exosi-EGR1 (Fig. 1C), suggesting a slight influence of si-EGR1 addition on the size of exosomes.
Fig. 1.
Construction of hUCMSCs-Exo containing si-EGR1.
Note: (A) Tracking si-EGR1-labeled hUCMSCs-Exo using Dil and observing under a fluorescence microscope (Scale bar = 25 μm); (B) Examining the morphological changes of exosomes after transfection using a transmission electron microscope (Scale bar = 100 nm); (C) Determining the particle diameter of transfected exosomes using DLS; (D) Measuring the hydrodynamic diameter changes of transfected exosomes; (E) Evaluating the zeta potential of transfected exosomes; (F) Assessing the degradation of naked si-EGR1 and si-EGR1 encapsulated in exosomes in vivo; (G) Evaluating the release kinetics of si-EGR1; (H) Investigating the impact of exosomes on cell viability using CCK-8 assay; (I) Co-culturing Dil-labeled hUCMSCs-Exo and Exosi-EGR1 with primary mouse cardiomyocytes and observing the internalization of exosomes (Scale bar = 25 μm). The experiment was repeated three times.
In vivo, the stability of exosomes is crucial for their application. Stability monitoring of Exosi-EGR1 was conducted for five days under conditions with 50 % fetal bovine serum (FBS). DLS analysis results indicated that these engineered exosomes maintained stability in terms of hydrodynamic diameter and surface zeta potential, demonstrating good physical stability of Exosi-EGR1 in simulated physiological environments (Fig. 1D and E).
Furthermore, to assess the degradation tolerance of si-EGR1 in vivo, Exosi-EGR1 was co-incubated with naked si-EGR1 in FBS for 24 h. The results showed that while naked si-EGR1 was undetectable after 4 h, si-EGR1 encapsulated within hUCMSCs-Exo remained detectable at 20 h. This finding emphasizes the advantage of exosomes as siRNA delivery vehicles, particularly in enhancing the stability of siRNA in serum (Fig. 1F).
Finally, the release kinetics of si-EGR1 were evaluated by incubating Exosi-EGR1 in PBS. After 24 h, the release rate in FBS reached 95 %, demonstrating efficient release performance (Fig. 1G). Additionally, CCK-8 cell viability detection confirmed that hUCMSCs-Exo and Exosi-EGR1 had no significant impact on the viability of primary mouse cardiomyocytes, even at concentrations as high as 500 μg/mL, thereby confirming the comparable biosafety of these engineered exosomes to natural exosomes (Fig. 1H). After co-culturing Dil-labeled hUCMSCs-Exo and Exosi-EGR1 with primary mouse cardiomyocytes for 24 h, it was observed that cardiomyocytes were able to internalize hUCMSCs-Exo and Exosi-EGR1 (Fig. 1I).
In conclusion, our study successfully demonstrated the efficient loading of si-EGR1 into hUCMSCs-Exo using electroporation technology and proved the potential application value of this method in enhancing siRNA stability and delivery efficiency.
4.3. Exosi-EGR1 mitigates MI/RI by alleviating oxidative stress and protecting mitochondrial function
In this study, we employed OGD/R treatment on primary mouse cardiomyocytes to simulate MI/RI. Cells were subjected to 3 h of OGD followed by reoxygenation for varying durations (0, 2, 4, 6, and 8 h). Cell viability was assessed at each point in time. The results revealed a significant decrease in cell viability after 3 h of OGD and 4 h of reoxygenation (Fig. 2A). Therefore, we selected 3 h of OGD followed by 4 h of reoxygenation for subsequent experiments (Fig. 2B). Experimental findings demonstrated that treatment with Exo significantly improved the decreased cell viability induced by OGD/R, with the therapeutic effect of Exosi-EGR1 surpassing that of hUCMSCs-Exo (Fig. 2C).
Fig. 2.
Effects of hUCMSCs-Exosi-EGR1 on OGD/R-induced mitochondrial oxidative stress.
Note: (A) Monitoring changes in cell viability under different OGD/R conditions; (B) Diagram illustrating the design of in vitro experiments; (C) Investigating the effect of Exo treatment on OGD/R-induced cell viability; (D) Observing changes in intracellular ROS levels using DCFH-DA fluorescence probe; (E-F) Measuring changes in MDA and SOD levels in cells using assay kits; (G) Detecting changes in mitochondrial membrane potential using JC-1 staining. ∗ indicates P < 0.05 compared to the Control group, ∗∗ indicates P < 0.01, ∗∗∗ indicates P < 0.001; # indicates P < 0.05 compared to the OGD/R group, ## indicates P < 0.01; & indicates P < 0.05 compared to the hUCMSCs-Exo group. The cell experiment was repeated three times.
Furthermore, we measured the levels of intracellular reactive oxygen species (ROS) using the DCFH-DA fluorescent probe. The results showed that OGD/R treatment markedly increased ROS levels, while treatment with Exo effectively reduced ROS levels (Fig. 2D). Additionally, the contents of MDA and SOD were examined. OGD/R treatment resulted in a significant increase in MDA levels and a decrease in SOD levels, whereas treatment with Exo significantly reduced MDA levels and enhanced SOD levels (Fig. 2E and F). Moreover, by detecting changes in mitochondrial membrane potential, we observed a decrease in mitochondrial membrane potential and an increase in the number of cells labeled with JC-1, indicating an increase in damaged mitochondria after OGD/R treatment. In contrast, treatment with Exo increased mitochondrial membrane potential and reduced the number of damaged mitochondria (Fig. 2G). Through these experiments, we found that Exosi-EGR1 exhibited superior therapeutic effects compared to hUCMSCs-Exo. These findings highlight the potential of Exo, especially Exosi-EGR1, in alleviating cardiomyocyte injury induced by OGD/R by effectively mitigating oxidative stress and protecting mitochondrial function.
4.4. hUCMSCs-Exosi-EGR1 promotes autophagy and suppresses apoptosis in OGD/R-induced cellular environment
Damaged mitochondria release cytochrome C into the cytoplasm, thereby promoting apoptosis [39]. To further assess the content of cytochrome C in both the mitochondria and cytoplasm, we conducted experiments. The results demonstrated a significant increase in cytoplasmic cytochrome C expression following OGD/R treatment, while Exo treatment resulted in decreased cytoplasmic cytochrome C levels (Fig. 3A–C). Given the crucial role of EGR1 in MI/RI-related cellular autophagy, as previously uncovered [50], we hypothesized that Exosi-EGR1 could suppress OGD/R-induced apoptosis through the regulation of mitophagy. By using TEM to observe autophagosomes in different experimental groups, we found that OGD/R treatment increased the number of mitophagosomes, while Exosi-EGR1 treatment further augmented the number of autophagosomes (Fig. 3D). Mitotracker labeling of mitochondria was used to evaluate mitophagy in conjunction with LC3-GFP co-localization. The results revealed enhanced mitophagy following OGD/R treatment, with Exo treatment further promoting mitophagy, while Exosi-EGR1 exhibited the most significant enhancement (Fig. 3E). Furthermore, western blot analysis of autophagy-related proteins in the mitochondria indicated that OGD/R treatment increased the LC3II/LC3I ratio and decreased p62 protein expression. In contrast, Exo treatment further elevated the LC3II/LC3I ratio and reduced p62 expression (Fig. 3F–H). This further confirmed the role of Exosi-EGR1 in promoting mitophagy.
Fig. 3.
Effects of hUCMSCs-Exosi-EGR1 on OGD-induced mitophagy and apoptosis.
Note: (A-C) Detecting the expression changes of cytochrome C in mitochondria and cytoplasm in cells from different groups using Western blot; (D) Observing mitophagy vesicles in cells from different groups using transmission electron microscope (bar = 1 μm, red arrows indicating autophagosomes); (E) Assessing mitophagy by co-localization analysis of Mitotracker Red and LC3-GFP in cells from different groups, labeled with Mitotracker to mark mitochondria (bar = 50 μm); (F-H) Analyzing the expression levels of LC3II, LC3I, and p62 in mitochondria of cells from different groups using Western blot. ∗ indicates P < 0.05 compared to the Control group, ∗∗ indicates P < 0.01, ∗∗∗ indicates P < 0.001; # indicates P < 0.05 compared to the OGD/R group, ## indicates P < 0.01; & indicates P < 0.05 compared to the hUCMSCs-Exo group. The cell experiment was repeated three times.
Additionally, apoptosis evaluation using TUNEL staining revealed a significant increase in apoptotic cell numbers following OGD/R treatment, which was effectively suppressed by Exo treatment (Fig. 4A and B). Flow cytometry analysis of apoptosis yielded consistent results with TUNEL staining (Fig. 4C and D). Moreover, we examined the expression changes of apoptosis-related proteins. The results demonstrated that OGD/R treatment significantly downregulated the expression of the anti-apoptotic protein Bcl-2 while increasing the expression of Bax and cleaved-caspase3. However, Exo treatment effectively reversed these protein expression changes induced by OGD/R (Fig. 4E–H).
Fig. 4.
Effects of hUCMSCs-Exosi-EGR1 on OGD-induced apoptosis.
Note: (A-B) Apoptosis using TUNEL fluorescence staining (bar = 50 μm); (C-D) Examining apoptosis in cells from different groups using flow cytometry; (E-H) Analyzing the expression levels of Bax, Bcl2, caspase3, and cleaved-caspase3 in cells from different groups using Western blot. ∗ indicates P < 0.05 compared to the Control group, ∗∗ indicates P < 0.01, ∗∗∗ indicates P < 0.001; # indicates P < 0.05 compared to the OGD/R group, ## indicates P < 0.01; & indicates P < 0.05 compared to the hUCMSCs-Exo group. The cell experiment was repeated three times.
In summary, these findings clearly indicate the significant role of hUCMSCs-Exosi-EGR1 in the OGD/R-induced cellular environment. It not only promotes the autophagy process but also effectively suppresses apoptosis, showcasing its potential application value in myocardial protection and injury repair.
Evaluation of Mechanical Strength, Adhesion Properties and Drug Release Performance of GelMA Hydrogel-Based MN Patch for Drug Delivery to Cardiac Tissue.
MN patches can be utilized to directly deliver drugs to cardiac tissue, enhancing local drug concentration and reducing systemic side effects. Several studies have reported the application of MN patches in treating myocardial infarction [25,47]. In this study, GelMA hydrogel was selected as the material for the MN patch due to its high biocompatibility and bioactivity, making it particularly suitable for medical devices and drug delivery systems. The preparation process of the MN patch involves precise microfabrication techniques. Initially, GelMA solution was poured into a negative mold made of polydimethylsiloxane (PDMS). These molds precisely defined the shape and dimensions of the MNs (a total of 385 cone-shaped arrays with a diameter of 17.5 mm, a conical length of 570 μm, and a base diameter of 260 μm) (Fig. 5A). Subsequently, a mixture solution was exposed to 365 nm ultraviolet light to induce the gelation of GelMA and form the MN structure (Fig. 5B–D). Exosomes were first labeled with Dil dye for visualization and tracking in subsequent experiments. hUCMSCs-Exo and hUCMSCs-Exosi-EGR1 were loaded into GelMA MNs using an immersion method, ensuring uniform distribution of exosomes throughout the entire structure of the MNs, ensuring uniformity and effectiveness of drug delivery (Fig. 5E).
Fig. 5.
Preparation and characterization of MN patch containing hUCMSCs-Exosi-EGR1.
Note: (A) Experimental design of MN patch with hUCMSCs-Exosi-EGR1; (B) Optical image of the MN patch; (C-D) Representative scanning electron microscope images of the MN patch (C: Scale bar = 500 μm; D: Scale bar = 100 μm); (E) Fluorescence microscopy image showing labeled exosomes and MN patch (Scale bar = 100 μm); (F) Compression mechanical properties of the MN patch; (G) Quantification of Dil release concentration in PBS after immersing the Exo-loaded MN patch; (H) The adhesion strength of the MN patch on the wet surface of the mouse LV tissue (n = 3); (I) The release of siRNA from the EGR1 siRNA-MN MN group was assessed in vitro using an ultraviolet spectrophotometer.
Furthermore, the mechanical strength of the MN patch was assessed. The MN patch was placed horizontally on a fixed platform, and a force sensor approached the tip of the MNs gradually. Measurement began when the sensor made contact with the tip until it was lowered by 0.3 mm. The results showed that the mechanical strength of each MN was approximately 0.3 N (Fig. 5F), sufficient to penetrate cardiac tissue effectively without rupture. Then, the Exo-loaded MN patch was immersed in PBS to quantify the release concentration of Dil in PBS. The results demonstrated that over time, the fluorescence signal of the MN gradually decreased, indicating sustained release of the drug for at least 15 days (Fig. 5G). Additionally, the myocardial adhesion test in mice (Fig. 5H) revealed that the adhesion strength of the MN patch was 83 kPa, which is higher than the contraction-relaxation force of mouse myocardium (10–50 kPa). This finding indicates that the MN patch can be easily applied to the myocardial surface and adhere firmly without requiring sutures or additional adhesives [59]. The in vitro release of EGR1 siRNA from the MN patch was assessed using an ultraviolet spectrophotometer. The release profile showed that the MN patch released 80 % of the siRNA within 24 h, which was faster compared to the positive control group of EGR1 siRNA. These results indicate that EGR1 siRNA can be effectively released from the MN patch (Fig. 5I). The MN patch prepared in this study, containing hUCMSCs-Exosi-EGR1, effectively delivered drugs to the heart and exhibited good mechanical strength, adhesion properties and drug release performance.
4.5. Significant effects of MN-hUCMSCs-Exosi-EGR1 patch on the treatment of MI/RI
To investigate the therapeutic effects of the MN patch containing Exosi-EGR1 on mouse MI/RI, we applied the patch on a mouse MI/RI model and conducted a series of treatments. As depicted in Fig. 6A, male mice were randomly divided into four groups and underwent MI/RI surgery by ligating the LAD artery. After ligating for 5 min, the patch was secured in the ischemic area of the myocardium, ischemia was induced for 30 min, and then the ligation was released for 60 min of reperfusion. The sham group only had their chests opened without surgery. Throughout the experiment, the cardiac function of the mice was evaluated using ultrasound cardiograpasound cardiography (UCG) on days 3, 7, 14, and 28 after administration.
Fig. 6.
Histological staining observation of the therapeutic effect of MN patch on MI/RI mice.
Note: (A) Experimental process of animal experiments; (B) Degradation of the patch in myocardial tissue observed through H&E staining (Scale bar = 500 μm); (C) Dil-labeled exosomes in myocardial tissue 7 days and 14 days after patch implantation (Scale bar = 50 μm); (D) Changes in EGR1 expression in mouse myocardial tissue observed through immunohistochemical staining (Scale bar = 50 μm); (E) Images of Masson, H&E, and Sirius Red staining of mouse myocardial tissue (Scale bar = 1 mm/100 μm); (F) Quantification of collagen fiber area percentage based on Masson staining; (G) Quantification of Sirius Red staining area percentage. ∗ indicates P < 0.05 compared to the Sham group, ∗∗ indicates P < 0.01; # indicates P < 0.05 compared to the MI/RI group, ## indicates P < 0.01; & indicates P < 0.05 compared to the MN-hUCMSCs-Exo group, && indicates P < 0.01. There were at least 6 mice in each group.
Histology and immunofluorescence were performed to observe the degradation of the patch and the absorption of exosomes by the myocardial tissue. As shown in Fig. 6B, the patch gradually degraded after seven days of implantation and completely degraded by day 14. The immunofluorescence results also demonstrated the successful uptake of exosomes by the myocardial tissue (Fig. 6C). The expression of EGR1 in the myocardial tissue on day 7 was further examined using immunohistochemical staining. The results revealed a significant increase in EGR1 expression in the MI/RI group compared to the sham group. The MN-hUCMSCs-Exo group showed a decrease in EGR1 expression compared to the MI/RI group, but the MN-Exosi-EGR1 group exhibited a more pronounced reduction (Fig. 6D). Pathological examination and molecular biology analysis of the cardiac tissue were further conducted. Masson's trichrome staining indicated a significant reduction in cardiac fibrosis in both the MN-hUCMSCs-Exo and MN-Exosi-EGR1 groups compared to the MI/RI group. Particularly, the MN-Exosi-EGR1 group showed the lowest degree of cardiac fibrosis, suggesting the significant therapeutic potential of the MN-Exosi-EGR1 patch in alleviating myocardial injury and promoting cardiac repair (Fig. 6E–G). Additionally, H&E staining revealed the alleviation of inflammation reaction in the cardiac tissue and improvement in the changes of cardiac cell gap in both the MN-hUCMSCs-Exo and MN-Exosi-EGR1 groups, further verifying the protective effect of the patch on cardiac tissue structure. Additionally, RT-qPCR, fluorescence co-localization, and organelle-targeting analyses demonstrated that MN-Exo@si-EGR1 exerted targeted effects primarily within myocardial cells and localized to the nucleus (Fig. S3).
In addition to histopathological examinations, cardiac function was also evaluated. M-mode two-dimensional echocardiography results showed that the LVPW thickness significantly increased in the MI/RI group compared to the Sham group (P < 0.05, Table S2). Moreover, small-animal ultrasound M-mode images revealed thickened anterior and posterior walls of the left ventricle and reduced cardiac contractile function (Fig. 7A). In contrast, both the hUCMSCs-Exo group and hUCMSCs-Exo@si-EGR1 group exhibited significant improvements in anterior and posterior wall thickness after treatment, with notably enhanced cardiac function (Fig. 7A) and a marked reduction in posterior wall thickness (Table S2). The results showed a significant decrease in LVEF and LVFS in the MI/RI group on day 3 after surgery compared to the sham group. In contrast, the LVEF and LVFS in the hUCMSCs-Exo and hUCMSCs-Exosi-EGR1 groups significantly improved after treatment, particularly on day 28, indicating the positive impact of MN-hUCMSCs-Exo and MN-Exosi-EGR1 treatments on cardiac function. Notably, the MN-Exosi-EGR1 group exhibited better therapeutic effects with higher LVEF and LVFS values compared to the MN-hUCMSCs-Exo group (Fig. 7B and C). This result suggests that the MN-Exosi-EGR1 patch may provide additional cardiac protection through targeted silencing of the EGR1 gene. Furthermore, the expression levels of fibrosis-related genes (MMP-2, TGF-β1, and MMP-9) in the myocardial tissue were determined by RT-qPCR. The results demonstrated a significant decrease in the expression of MMP-2, TGF-β1, and MMP-9 in the MN-hUCMSCs-Exo and MN-Exosi-EGR1 groups compared to the MI/RI group, indicating that the patch treatment significantly improved cardiac fibrosis in the injured heart (Fig. 7D–F) (P < 0.05).
Fig. 7.
Observation of the improvement of cardiac function in MI/RI mice by MN patch.
Note: (A) Ultrasound examination of mice after patch implantation, recorded at 3 days, 7 days, 14 days, and 28 days; (B-C) Quantitative analysis of LVEF and LVSF in mice using ultrasound examination after patch implantation, including results at 3 days, 7 days, 14 days, and 28 days; (D-F) mRNA levels of MMP-9, MMP-2, and TGF-β1 in mouse myocardial tissue detected through RT-qPCR 28 days after patch implantation. ∗ indicates P < 0.05 compared to the Sham group, ∗∗ indicates P < 0.01, ∗∗∗ indicates P < 0.001; # indicates P < 0.05 compared to the MI/RI group, ### indicates P < 0.001; & indicates P < 0.05 compared to the MN-hUCMSCs-Exo group. There were at least 6 mice in each group.
In summary, the MN-hUCMSCs-Exo and MN-Exosi-EGR1 patches exhibited significant therapeutic effects in an MI/RI model. Particularly, the MN-Exosi-EGR1 patch showed more remarkable effects in promoting cardiac functional recovery, reducing cardiac fibrosis, and alleviating inflammation reactions, providing a new strategy for the treatment of MI/RI.
4.6. MN patch promotes cardiomyocyte autophagy and inhibits apoptosis
In this study, we further investigated the impact of the MN patch on MI/RI in mice, focusing on cardiomyocyte mitophagy and apoptosis. First, 8-OHdG staining revealed a significant increase in 8-OHdG accumulation in the MI/RI group compared to the Sham group. However, in the MN-hUCMSCs-Exo group and MN-Exosi-EGR1 group, there was a significant reduction in 8-OHdG accumulation in cardiomyocytes compared to the MI/RI group, indicating that the MN patch can improve the oxidative stress state of cardiomyocytes (Fig. 8A and B). Furthermore, TEM analysis of mitophagosomes showed a significant increase in the number of autophagic bodies in the MN-hUCMSCs-Exo group and MN-Exosi-EGR1 group compared to the MI/RI group, suggesting that the MN patch enhances cardiomyocyte autophagy activity (Fig. 8C and D). Mitotracker co-localization analysis of Mitotracker Red and LC3-GFP in cardiac tissue revealed an increase in mitophagy in the MI/RI group compared to the Sham group. Treatment with the MN patch further promoted the increase in mitophagy activity, particularly in the Exosi-EGR1 group (Fig. 8E and F).
Fig. 8.
Effects of MN patch on cardiomyocyte mitophagy and apoptosis in MI/RI mice.
Note: (A-B) Accumulation of 8-OHdG in mouse cardiomyocytes observed through 8-OHdG staining (Scale bar = 50 μm); (C-D) Observation of mitophagosomes in cardiomyocytes using a transmission electron microscope (Scale bar = 500 nm, the red arrow indicates autophagosome); (E-F) Evaluation of mitophagy through co-localization analysis of Mitotracker Red and LC3-GFP in myocardial tissue (Scale bar = 50 μm); (G-H) Cardiomyocyte apoptosis observed through TUNEL staining (Scale bar = 50 μm); (I-J) Expression of Bax, Bcl2, caspase3, and cleaved-caspase3 in myocardial tissue detected through Western blot. ∗ indicates P < 0.05 compared to the Sham group, ∗∗ indicates P < 0.01, ∗∗∗ indicates P < 0.001; # indicates P < 0.05 compared to the MI/RI group, ### indicates P < 0.001; & indicates P < 0.05 compared to the MN-hUCMSCs-Exo group, && indicates P < 0.01. There were at least 6 mice in each group.
Regarding apoptosis, TUNEL staining results demonstrated a significant reduction in the number of apoptotic cells in the MN-hUCMSCs-Exo group and MN-Exosi-EGR1 group compared to the MI/RI group (Fig. 8G and H). Moreover, the expression of apoptosis-related protein Bcl-2 was upregulated in the hUCMSCs-Exo group and MN-Exosi-EGR1 group, while the expression of Bax and cleaved-caspase3 proteins was downregulated. These findings indicate that the MN patch effectively inhibits cardiomyocyte apoptosis (Fig. 8I and J).
In summary, the MN patch containing hUCMSCs-Exo and hUCMSCs-Exosi-EGR1 not only promotes cardiomyocyte autophagy but also effectively inhibits MI/RI-induced apoptosis. These results suggest that the MN patch may exert a protective effect against MI/RI by modulating cardiomyocyte autophagy and apoptosis processes, highlighting its potential therapeutic value in the treatment of heart disease.
5. Discussion
MI/RI is a common pathological process in ischemic heart disease, and current treatment methods have limitations. Therefore, there is an urgent need to find more effective therapeutic strategies [1,60,61]. This study explores a novel treatment method, the MN patch loaded with exosomes derived from hUCMSCs and containing EGR1 siRNA (hUCMSCs-Exosi-EGR1). The goal of this treatment strategy is to protect cardiomyocytes from MI/RI damage by regulating oxidative stress and mitophagy [62,63].
In the treatment of MI/RI, numerous studies have demonstrated the significant potential of using stem cells and exosomes as delivery vehicles for therapeutic strategies. Compared to other treatment strategies, the hUCMSCs-Exo loaded with EGR1 siRNA in this study has several unique features [64]. Firstly, exosomes have a cup-shaped morphology and an average diameter ranging from 30 to 100 nm, which contributes to their stability and penetration ability in vivo [65]. Secondly, the high expression of CD63 and HSP70 further verifies the specific protein expression of exosomes, which is associated with their function [[66], [67], [68]]. Finally, exosomes do not express Calnexin, confirming their purity and specific origin [69,70].
The prepared Exosi-EGR1 MN patch exhibits good physical stability and sustained drug release capability [[71], [72], [73]]. After being crosslinked and solidified by ultraviolet light, the loaded Exosi-EGR1 is capable of continuous release in simulated body fluid for more than 15 days, providing possibilities for long-term treatment [74]. Furthermore, the preparation method of the MN patch is simple and feasible while demonstrating good mechanical strength, which contributes to its operability and reliability in clinical applications [[71], [72], [73]].
In vitro, experimental results show that Exosi-EGR1 exhibits significant protective effects on cardiomyocytes undergoing OGD/R treatment. This therapeutic strategy enhances the viability of cardiomyocytes, reduces ROS levels, increases the LC3-II/LC3-I ratio, and significantly decreases the expression of p62 protein [52,75]. These results indicate that Exosi-EGR1 has the ability to regulate oxidative stress and promote mitophagy.
In vivo, experimental results demonstrate that the Exosi-EGR1 MN patch treatment significantly improves cardiac function, reduces cardiac fibrosis, and lowers apoptosis rates in mice. Compared to hUCMSCs-Exo without si-EGR1 loading, the Exosi-EGR1 treatment group exhibits better cardiac protective effects. These results further confirm the effectiveness of this treatment strategy in an MI/RI animal model.
In summary, this study demonstrates the therapeutic potential of hUCMSCs-Exo and engineered hUCMSCs-Exosi-EGR1 in an MI/RI model. Through electroporation technology, siRNA specifically targeting the EGR1 gene (si-EGR1) is successfully loaded into Exo, leading to a significant improvement in oxidative stress, promotion of mitophagy, and inhibition of apoptosis in cardiomyocytes. Additionally, the developed MN patch containing hUCMSCs-Exosi-EGR1 delivers the drug directly to the cardiac tissue, effectively enhancing the treatment effectiveness, particularly in promoting cardiac function recovery, reducing cardiac fibrosis, and alleviating inflammation response.
The scientific and clinical value of this study lies in the exploration of a novel strategy for treating MI/RI. Although some progress has been made with existing treatment methods, they still face numerous challenges. In this study, an MN patch was prepared using exosomes derived from hUCMSCs loaded with EGR1 siRNA, and its regulatory effects on oxidative stress and mitophagy were evaluated in a model. The experimental results demonstrated that the MN patch significantly protected cardiomyocytes from injury and improved cardiac function. Therefore, this strategy holds potential clinical applications and may serve as a promising approach for MI/RI treatment.
However, several limitations exist in this study. Firstly, a mouse model was used, which may differ from humans in physiological and pathological characteristics. Larger animals, such as dogs or pigs, share greater anatomical and physiological similarities with humans in terms of size, lifespan, and tissue structure. Further studies with prolonged follow-up in large animal MI/RI models are necessary to confirm the suitability of the nanoparticle patch system [76]. Secondly, while the experimental results indicate significant protective effects of the MN patch, further clinical research is needed to validate its therapeutic efficacy and safety. Additionally, the fabrication and application of the MN patch still face some technical challenges that require further optimization and improvement.
Regarding future prospects, several aspects can be considered. Firstly, other potential therapeutic drugs or gene carriers can be explored within the MN patch to improve treatment effectiveness. Secondly, more preclinical studies can be conducted to validate the efficacy of the MN patch in different animal models and tissue models. Lastly, clinical trials can be considered to evaluate the clinical efficacy and safety of the MN patch in clinical practice. Through these endeavors, more effective and safe methods can be provided for the treatment of MI/RI.
CRediT authorship contribution statement
Chen Huang: Conceptualization. Xun Zhang: Conceptualization. Shi-Xiong Wu: Conceptualization. Qing Chang: Data curation. Zhi-Kun Zheng: Conceptualization. Jing Xu: Conceptualization.
Ethical statement
All animal experiments were approved by the Animal Ethics Committee of The First Affiliated Hospital of Zhengzhou University.
Funding
This study was supported by National Natural Science Foundation of China Youth Fund (82300314).
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgment
None.
Footnotes
Supplementary data to this article can be found online at https://doi.org/10.1016/j.mtbio.2025.101500.
Appendix A. Supplementary data
The following are the Supplementary data to this article:
figs1.
figs2.
figs3.
Data availability
Data will be made available on request.
References
- 1.Zhao Y., Lu X., Wan F., Gao L., Lin N., He J., Wei L., Dong J., Qin Z., Zhong F., Qiao Z., Wang W., Ge H., Ding S., Yang Y., Xiu J., Shan P., Yan F., Zhao S., Ji Y., Pu J. Disruption of circadian rhythms by shift work exacerbates reperfusion injury in myocardial infarction. J. Am. Coll. Cardiol. 2022;79:2097–2115. doi: 10.1016/j.jacc.2022.03.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Su X., Zhou M., Li Y., Zhang J., An N., Yang F., Zhang G., Yuan C., Chen H., Wu H., Xing Y. Protective effects of natural products against myocardial ischemia/reperfusion: mitochondria-targeted therapeutics. Biomed. Pharmacother. 2022;149 doi: 10.1016/j.biopha.2022.112893. [DOI] [PubMed] [Google Scholar]
- 3.Li Y., Meng Q., Wang L., Cui Y. TRIM27 protects against cardiac ischemia-reperfusion injury by suppression of apoptosis and inflammation via negatively regulating p53. Biochem. Biophys. Res. Commun. 2021;557:127–134. doi: 10.1016/j.bbrc.2021.03.061. [DOI] [PubMed] [Google Scholar]
- 4.Shook P.L., Singh M., Singh K. Macrophages in the inflammatory phase following myocardial infarction: role of exogenous ubiquitin. Biology. 2023;12:1258. doi: 10.3390/biology12091258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Zhou M., Yu Y., Luo X., Wang J., Lan X., Liu P., Feng Y., Jian W. Myocardial ischemia-reperfusion injury: therapeutics from a mitochondria-centric perspective. Cardiology. 2021;146:781–792. doi: 10.1159/000518879. [DOI] [PubMed] [Google Scholar]
- 6.Zhang J., Liang R., Wang K., Zhang W., Zhang M., Jin L., Xie P., Zheng W., Shang H., Hu Q., Li J., Chen G., Wu F., Lan F., Wang L., Wang S.-Q., Li Y., Zhang Y., Liu J., Lv F., Hu X., Xiao R.-P., Lei X., Zhang Y. Novel CaMKII-δ inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit tumor growth. Circulation. 2022;145:1154–1168. doi: 10.1161/circulationaha.121.055920. [DOI] [PubMed] [Google Scholar]
- 7.Lebek S., Chemello F., Caravia X.M., Tan W., Li H., Chen K., Xu L., Liu N., Bassel-Duby R., Olson E.N. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science. 2023;379:179–185. doi: 10.1126/science.ade1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Xie Y., Li Y., Chen J., Ding H., Zhang X. Early growth response-1: key mediators of cell death and novel targets for cardiovascular disease therapy. Front. Cardiovasc. Med. 2023;10 doi: 10.3389/fcvm.2023.1162662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Rayner B.S., Figtree G.A., Sabaretnam T., Shang P., Mazhar J., Weaver J.C., Lay W.N., Witting P.K., Hunyor S.N., Grieve S.M., Khachigian L.M., Bhindi R. Selective inhibition of the master regulator transcription factor egr‐1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction. JAHA. 2013;2 doi: 10.1161/jaha.113.000023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Yang Q., Murata K., Ikeda T., Minatoya K., Masumoto H. miR-124-3p downregulates EGR1 to suppress ischemia-hypoxia reperfusion injury in human iPS cell-derived cardiomyocytes. Sci. Rep. 2024;14 doi: 10.1038/s41598-024-65373-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Richter M., Vader P., Fuhrmann G. Approaches to surface engineering of extracellular vesicles. Adv. Drug Deliv. Rev. 2021;173:416–426. doi: 10.1016/j.addr.2021.03.020. [DOI] [PubMed] [Google Scholar]
- 12.Wu H., Zhang Z., Zhang Y., Zhao Z., Zhu H., Yue C. Extracellular vesicle: a magic lamp to treat skin aging, refractory wound, and pigmented dermatosis? Front. Bioeng. Biotechnol. 2022;10 doi: 10.3389/fbioe.2022.1043320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Shen S., Huang J., Xu C., Shen Y., Jiang S., Li Y., Wang H., Zhang M. ERK modulates macrophage polarization and alters exosome miRNA expression in diabetic nephropathy. Clin. Lab. 2021;67 doi: 10.7754/clin.lab.2021.210314. [DOI] [PubMed] [Google Scholar]
- 14.Huang C., Luo W., Wang Q., Ye Y., Fan J., Lin L., Shi C., Wei W., Chen H., Wu Y., Tang Y. Human mesenchymal stem cells promote ischemic repairment and angiogenesis of diabetic foot through exosome miRNA-21-5p. Stem Cell Res. 2021;52 doi: 10.1016/j.scr.2021.102235. [DOI] [PubMed] [Google Scholar]
- 15.Liu X., Yuan J., Wu Z., Zhang J., Shen Y., Jia J. Plasma exosome miRNA-26b-3p derived from idiopathic short stature impairs longitudinal bone growth via the AKAP2/ERK1/2 axis. J. Nanobiotechnol. 2023;21 doi: 10.1186/s12951-023-01849-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Cheng Y.-C., Chang Y.-A., Chen Y.-J., Sung H.-M., Bogeski I., Su H.-L., Hsu Y.-L., Wang H.-M.D. The roles of extracellular vesicles in malignant melanoma. Cells. 2021;10:2740. doi: 10.3390/cells10102740. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Xu J., Wang J., Chen Y., Hou Y., Hu J., Wang G. Recent advances of natural and bioengineered extracellular vesicles and their application in vascular regeneration. Regenerative Biomaterials. 2022;9 doi: 10.1093/rb/rbac064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Jiang X., Lei R. Extracellular lncRNAs secreted and absorbed by cardiomyocytes. J of Cellular Biochemistry. 2023;124:785–796. doi: 10.1002/jcb.30425. [DOI] [PubMed] [Google Scholar]
- 19.Liu Y., Chen J., Liang H., Cai Y., Li X., Yan L., Zhou L., Shan L., Wang H. Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling. Stem Cell Res. Ther. 2022;13 doi: 10.1186/s13287-022-02927-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Li K., Yan G., Huang H., Zheng M., Ma K., Cui X., Lu D., Zheng L., Zhu B., Cheng J., Zhao J. Anti-inflammatory and immunomodulatory effects of the extracellular vesicles derived from human umbilical cord mesenchymal stem cells on osteoarthritis via M2 macrophages. J. Nanobiotechnol. 2022;20 doi: 10.1186/s12951-021-01236-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Teng L., Maqsood M., Zhu M., Zhou Y., Kang M., Zhou J., Chen J. Exosomes derived from human umbilical cord mesenchymal stem cells accelerate diabetic wound healing via promoting M2 macrophage polarization, angiogenesis, and collagen deposition. IJMS. 2022;23 doi: 10.3390/ijms231810421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zhang Y., Yan J., Li Z., Zheng J., Sun Q. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate psoriasis-like skin inflammation. J. Interferon Cytokine Res. 2022;42:8–18. doi: 10.1089/jir.2021.0146. [DOI] [PubMed] [Google Scholar]
- 23.Gao L., Zhou Q., Zhang Y., Sun S., Lv L., Ma P., Yang J., Liu M., Zhang L., Wang X., Zhan L. Dimethyl sulfoxide-free cryopreservation of human umbilical cord mesenchymal stem cells based on zwitterionic betaine and electroporation. IJMS. 2021;22:7445. doi: 10.3390/ijms22147445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Abas B.I., Demirbolat G.M., Cevik O. Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel. PLoS One. 2022;17 doi: 10.1371/journal.pone.0274607. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Yuan J., Yang H., Liu C., Shao L., Zhang H., Lu K., Wang J., Wang Y., Yu Q., Zhang Y., Yu Y., Shen Z. Microneedle patch loaded with exosomes containing MicroRNA‐29b prevents cardiac fibrosis after myocardial infarction. Adv Healthcare Materials. 2023;12 doi: 10.1002/adhm.202202959. [DOI] [PubMed] [Google Scholar]
- 26.Zhang Y., Gao Z., Chao S., Lu W., Zhang P. Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis. Drug Deliv. 2022;29:1934–1950. doi: 10.1080/10717544.2022.2089295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ju Y., Hu Y., Yang P., Xie X., Fang B. Extracellular vesicle-loaded hydrogels for tissue repair and regeneration. Materials Today Bio. 2023;18 doi: 10.1016/j.mtbio.2022.100522. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zhang W., Wang N., Yang M., Sun T., Zhang J., Zhao Y., Huo N., Li Z. Periosteum and development of the tissue-engineered periosteum for guided bone regeneration. Journal of Orthopaedic Translation. 2022;33:41–54. doi: 10.1016/j.jot.2022.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Liu Y., Li T., Sun M., Cheng Z., Jia W., Jiao K., Wang S., Jiang K., Yang Y., Dai Z., Liu L., Liu G., Luo Y. ZIF-8 modified multifunctional injectable photopolymerizable GelMA hydrogel for the treatment of periodontitis. Acta Biomater. 2022;146:37–48. doi: 10.1016/j.actbio.2022.03.046. [DOI] [PubMed] [Google Scholar]
- 30.Lee J., Park S., Le P.T., Lee G., Lee H.W., Yun G., Jeon J., Park J., Pham D.T., Park Y.S., Lim H., Kim C., Hwang T.S., Kim S.W., Lim G. Peripheral microneedle patch for first‐aid hemostasis. Adv Healthcare Materials. 2023;12 doi: 10.1002/adhm.202201697. [DOI] [PubMed] [Google Scholar]
- 31.Jin X., Zhang X., Li Y., Xu M., Yao Y., Wu Z., He Y., Gao J., Li B. Long-acting microneedle patch loaded with adipose collagen fragment for preventing the skin photoaging in mice. Biomater. Adv. 2022;135 doi: 10.1016/j.bioadv.2022.212744. [DOI] [PubMed] [Google Scholar]
- 32.Li W., Yang N., Tan X., Liu Z., Huang Y., Yuan R., Liu L., Ge L. Layer-by-layer microneedle patch with antibacterial and antioxidant dual activities for accelerating bacterial-infected wound healing. Colloids Surf. B Biointerfaces. 2023;231 doi: 10.1016/j.colsurfb.2023.113569. [DOI] [PubMed] [Google Scholar]
- 33.Feng H., Liu Q., Deng Z., Li H., Zhang H., Song J., Liu X., Liu J., Wen B., Wang T. Human umbilical cord mesenchymal stem cells ameliorate erectile dysfunction in rats with diabetes mellitus through the attenuation of ferroptosis. Stem Cell Res. Ther. 2022;13 doi: 10.1186/s13287-022-03147-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Jia Y., Ding X., Zhou L., Zhang L., Yang X. Retracted article: mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1. Oncogene. 2020;40:246–261. doi: 10.1038/s41388-020-01486-7. [DOI] [PubMed] [Google Scholar]
- 35.Cui Y., Guo Y., Kong L., Shi J., Liu P., Li R., Geng Y., Gao W., Zhang Z., Fu D. A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact. Mater. 2022;10:207–221. doi: 10.1016/j.bioactmat.2021.09.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Chen T., Deng Z., Zhao R., Shen H., Li W. SYKT alleviates doxorubicin‐induced cardiotoxicity via modulating ROS‐mediated p53 and MAPK signal pathways. Evid. base Compl. Alternative Med. 2018;2018 doi: 10.1155/2018/2581031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.He L., He T., Xing J., Zhou Q., Fan L., Liu C., Chen Y., Wu D., Tian Z., Liu B., Rong L. Bone marrow mesenchymal stem cell-derived exosomes protect cartilage damage and relieve knee osteoarthritis pain in a rat model of osteoarthritis. Stem Cell Res. Ther. 2020;11 doi: 10.1186/s13287-020-01781-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Xue Y., Fu W., Yu P., Li Y., Yu X., Xu H., Sui D. Ginsenoside rc alleviates myocardial ischemia-reperfusion injury by reducing mitochondrial oxidative stress and apoptosis: role of SIRT1 activation. J. Agric. Food Chem. 2023;71:1547–1561. doi: 10.1021/acs.jafc.2c06926. [DOI] [PubMed] [Google Scholar]
- 39.Cai Y., Yang E., Yao X., Zhang X., Wang Q., Wang Y., Liu J., Fan W., Yi K., Kang C., Wu J. FUNDC1-dependent mitophagy induced by tPA protects neurons against cerebral ischemia-reperfusion injury. Redox Biol. 2021;38 doi: 10.1016/j.redox.2020.101792. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Zhang S., Li R., Zheng Y., Zhou Y., Fan X. Erythrocyte membrane-enveloped salvianolic acid B nanoparticles attenuate cerebral ischemia-reperfusion injury. IJN. 2022;17:3561–3577. doi: 10.2147/ijn.s375908. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 41.Mao Z., Tian L., Liu J., Wu Q., Wang N., Wang G., Wang Y., Seto S. Ligustilide ameliorates hippocampal neuronal injury after cerebral ischemia reperfusion through activating PINK1/Parkin-dependent mitophagy. Phytomedicine. 2022;101 doi: 10.1016/j.phymed.2022.154111. [DOI] [PubMed] [Google Scholar]
- 42.Sui M., Xu D., Zhao W., Lu H., Chen R., Duan Y., Li Y., Zhu Y., Zhang L., Zeng L. CIRBP promotes ferroptosis by interacting with ELAVL1 and activating ferritinophagy during renal ischaemia‐reperfusion injury. J Cellular Molecular Medi. 2021;25:6203–6216. doi: 10.1111/jcmm.16567. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Yi X., Yan W., Guo T., Liu N., Wang Z., Shang J., Wei X., Cui X., Sun Y., Ren S., Chen L. Erythropoietin mitigates diabetic nephropathy by restoring PINK1/parkin-mediated mitophagy. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.883057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Su Y., Quan C., Li X., Shi Y., Duan P., Yang K. Mutual promotion of apoptosis and autophagy in prepubertal rat testes induced by joint exposure of bisphenol A and nonylphenol. Environmental Pollution. 2018;243:693–702. doi: 10.1016/j.envpol.2018.09.030. [DOI] [PubMed] [Google Scholar]
- 45.Wang Y., Xiao G., He S., Liu X., Zhu L., Yang X., Zhang Y., Orgah J., Feng Y., Wang X., Zhang B., Zhu Y. Protection against acute cerebral ischemia/reperfusion injury by QiShenYiQi via neuroinflammatory network mobilization. Biomed. Pharmacother. 2020;125 doi: 10.1016/j.biopha.2020.109945. [DOI] [PubMed] [Google Scholar]
- 46.Shin H., Choi H., So D., Kim Y., Cho K., Chung H., Lee K., Chun Y., Cho C., Kang G.H., Kim W.H., Park J. ITF2 prevents activation of the β-catenin–TCF4 complex in colon cancer cells and levels decrease with tumor progression. Gastroenterology. 2014;147:430–442.e8. doi: 10.1053/j.gastro.2014.04.047. [DOI] [PubMed] [Google Scholar]
- 47.Chen H., Fan L., Peng N., Yin Y., Mu D., Wang J., Meng R., Xie J. Galunisertib-loaded gelatin methacryloyl hydrogel microneedle patch for cardiac repair after myocardial infarction. ACS Appl. Mater. Interfaces. 2022;14:40491–40500. doi: 10.1021/acsami.2c05352. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Ptaszek L.M., Portillo Lara R., Shirzaei Sani E., Xiao C., Roh J., Yu X., Ledesma P.A., Hsiang Yu C., Annabi N., Ruskin J.N. Gelatin methacryloyl bioadhesive improves survival and reduces scar burden in a mouse model of myocardial infarction. JAHA. 2020;9 doi: 10.1161/jaha.119.014199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Walker B.W., Lara R.P., Yu C.H., Sani E.S., Kimball W., Joyce S., Annabi N. Engineering a naturally-derived adhesive and conductive cardiopatch. Biomaterials. 2019;207:89–101. doi: 10.1016/j.biomaterials.2019.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Huang C., Shu L., Zhang H., Zhu X., Huang G., Xu J. Circ_ZNF512-Mediated miR-181d-5p inhibition limits cardiomyocyte autophagy and promotes myocardial ischemia/reperfusion injury through an EGR1/mTORC1/TFEB-based mechanism. J. Med. Chem. 2022;65:1808–1821. doi: 10.1021/acs.jmedchem.1c00745. [DOI] [PubMed] [Google Scholar]
- 51.Zhao J., Li X., Hu J., Chen F., Qiao S., Sun X., Gao L., Xie J., Xu B. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc. Res. 2019;115:1205–1216. doi: 10.1093/cvr/cvz040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Li D., Song C., Zhang J., Zhao X. ROS and iron homeostasis dependent ferroptosis play a vital role in 5-Fluorouracil induced cardiotoxicity in vitro and in vivo. Toxicology. 2022;468 doi: 10.1016/j.tox.2022.153113. [DOI] [PubMed] [Google Scholar]
- 53.Bian J., Cai F., Chen H., Tang Z., Xi K., Tang J., Wu L., Xu Y., Deng L., Gu Y., Cui W., Chen L. Modulation of local overactive inflammation via injectable hydrogel microspheres. Nano Lett. 2021;21:2690–2698. doi: 10.1021/acs.nanolett.0c04713. [DOI] [PubMed] [Google Scholar]
- 54.Cui L., Bao H., Zhu W., Tang Y., Luo Q., Si Y., Fu Q., Jiang Z. hUMSCs transplantation regulates AMPK/NR4A1 signaling Axis to inhibit ovarian fibrosis in POI rats. Stem Cell Rev and Rep. 2022;19:1449–1465. doi: 10.1007/s12015-022-10469-y. [DOI] [PubMed] [Google Scholar]
- 55.Nie C., Ding X., A R., Zheng M., Li Z., Pan S., Yang W. Hydrogen gas inhalation alleviates myocardial ischemia-reperfusion injury by the inhibition of oxidative stress and NLRP3-mediated pyroptosis in rats. Life Sci. 2021;272 doi: 10.1016/j.lfs.2021.119248. [DOI] [PubMed] [Google Scholar]
- 56.Hou Z., Yang F., Chen K., Wang Y., Qin J., Liang F. hUC-MSC-EV-miR-24 enhances the protective effect of dexmedetomidine preconditioning against myocardial ischemia–reperfusion injury through the KEAP1/Nrf2/HO-1 signaling. Drug Deliv. and Transl. Res. 2023;14:143–157. doi: 10.1007/s13346-023-01388-7. [DOI] [PubMed] [Google Scholar]
- 57.Zou Y., Li L., Li Y., Chen S., Xie X., Jin X., Wang X., Ma C., Fan G., Wang W. Restoring cardiac functions after myocardial infarction–ischemia/reperfusion via an exosome anchoring conductive hydrogel. ACS Appl. Mater. Interfaces. 2021;13:56892–56908. doi: 10.1021/acsami.1c16481. [DOI] [PubMed] [Google Scholar]
- 58.An Z., Tian J., Liu Y., Zhao X., Yang X., Yong J., Liu L., Zhang L., Jiang W., Song X., Zhang H. Exosomes as a cell-free therapy for myocardial injury following acute myocardial infarction or ischemic reperfusion. Aging and Disease. 2022;13:1770. doi: 10.14336/ad.2022.0416. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Münch J., Abdelilah-Seyfried S. Sensing and responding of cardiomyocytes to changes of tissue stiffness in the diseased heart. Front. Cell Dev. Biol. 2021;9 doi: 10.3389/fcell.2021.642840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Prag H.A., Aksentijevic D., Dannhorn A., Giles A.V., Mulvey J.F., Sauchanka O., Du L., Bates G., Reinhold J., Kula-Alwar D., Xu Z., Pellerin L., Goodwin R.J.A., Murphy M.P., Krieg T. Ischemia-selective cardioprotection by malonate for ischemia/reperfusion injury. Circ. Res. 2022;131:528–541. doi: 10.1161/circresaha.121.320717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Wang K., Li Y., Qiang T., Chen J., Wang X. Role of epigenetic regulation in myocardial ischemia/reperfusion injury. Pharmacol. Res. 2021;170 doi: 10.1016/j.phrs.2021.105743. [DOI] [PubMed] [Google Scholar]
- 62.Wang M., Pan W., Xu Y., Zhang J., Wan J., Jiang H. Microglia-Mediated neuroinflammation: a potential target for the treatment of cardiovascular diseases. JIR. 2022;15:3083–3094. doi: 10.2147/jir.s350109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Rabinovich-Nikitin I., Rasouli M., Reitz C.J., Posen I., Margulets V., Dhingra R., Khatua T.N., Thliveris J.A., Martino T.A., Kirshenbaum L.A. Mitochondrial autophagy and cell survival is regulated by the circadian Clock gene in cardiac myocytes during ischemic stress. Autophagy. 2021;17:3794–3812. doi: 10.1080/15548627.2021.1938913. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Yang F., Zhang A., Richardson D.W. Regulation of the tenogenic gene expression in equine tenocyte-derived induced pluripotent stem cells by mechanical loading and Mohawk. Stem Cell Res. 2019;39 doi: 10.1016/j.scr.2019.101489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Zhao L.-R., Mao J.-Q., Zhao B.-J., Chen J. Isolation and biological characteristics of exosomes derived from periodontal ligament stem cells. Shang Hai Kou Qiang Yi Xue. 2019;28:343–348. [PubMed] [Google Scholar]
- 66.Tan K.L., Chia W.C., How C.W., Tor Y.S., Show P.L., Looi Q.H.D., Foo J.B. Benchtop isolation and characterisation of small extracellular vesicles from human mesenchymal stem cells. Mol. Biotechnol. 2021;63:780–791. doi: 10.1007/s12033-021-00339-2. [DOI] [PubMed] [Google Scholar]
- 67.Kumar S., Crenshaw B.J., Williams S.D., Bell C.R., Matthews Q.L., Sims B. Cocaine‐specific effects on exosome biogenesis in microglial cells. Neurochem. Res. 2021;46:1006–1018. doi: 10.1007/s11064-021-03231-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Qazi R. e M., Sajid Z., Zhao C., Hussain I., Iftikhar F., Jameel M., Rehman F.U., Mian A.A. vol. 24. 2023. (Lyophilization Based Isolation of Exosomes, IJMS). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Sedykh S.E., Purvinsh L.V., Burkova E.E., Dmitrenok P.S., Ryabchikova E.I., Nevinsky G.A. Analysis of proteins and peptides of highly purified CD9+ and CD63+ horse milk exosomes isolated by affinity chromatography. IJMS. 2022;23 doi: 10.3390/ijms232416106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Ai Y., Guo C., Garcia-Contreras M., Sánchez B L.S., Saftics A., Shodubi O., Raghunandan S., Xu J., Tsai S.J., Dong Y., Li R., Jovanovic-Talisman T., Gould S.J. Syntenin and CD63 promote exosome biogenesis from the plasma membrane by blocking cargo endocytosis. 2023. [DOI]
- 71.Dobrocky T., Nicholson P., Häni L., Mordasini P., Krings T., Brinjikji W., Cutsforth-Gregory J.K., Schär R., Schankin C., Gralla J., Pereira V.M., Raabe A., Farb R., Beck J., Piechowiak E.I. Spontaneous intracranial hypotension: searching for the CSF leak. Lancet Neurol. 2022;21:369–380. doi: 10.1016/s1474-4422(21)00423-3. [DOI] [PubMed] [Google Scholar]
- 72.Ma W., Zhang X., Liu Y., Fan L., Gan J., Liu W., Zhao Y., Sun L. Polydopamine decorated microneedles with Fe‐MSC‐Derived nanovesicles encapsulation for wound healing. Adv. Sci. 2022;9 doi: 10.1002/advs.202103317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Theocharidis G., Yuk H., Roh H., Wang L., Mezghani I., Wu J., Kafanas A., Contreras M., Sumpio B., Li Z., Wang E., Chen L., Guo C.F., Jayaswal N., Katopodi X.-L., Kalavros N., Nabzdyk C.S., Vlachos I.S., Veves A., Zhao X. A strain-programmed patch for the healing of diabetic wounds. Nat. Biomed. Eng. 2022;6:1118–1133. doi: 10.1038/s41551-022-00905-2. [DOI] [PubMed] [Google Scholar]
- 74.Azaman F.A., Zhou K., Blanes-Martínez M. del M., Brennan Fournet M., Devine D.M. Bioresorbable chitosan-based bone regeneration scaffold using various bioceramics and the alteration of photoinitiator concentration in an extended UV photocrosslinking reaction. Gels. 2022;8:696. doi: 10.3390/gels8110696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Jiang Q., Dong X., Hu D., Chen L., Luo Y. Aquaporin 4 inhibition alleviates myocardial ischemia-reperfusion injury by restraining cardiomyocyte pyroptosis. Bioengineered. 2021;12:9021–9030. doi: 10.1080/21655979.2021.1992332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Chen X., Chen H., Zhu L., Zeng M., Wang T., Su C., Vulugundam G., Gokulnath P., Li G., Wang X., Yao J., Li J., Cretoiu D., Chen Z., Bei Y. Nanoparticle–patch system for localized, effective, and sustained miRNA administration into infarcted myocardium to alleviate myocardial ischemia–reperfusion injury. ACS Nano. 2024 doi: 10.1021/acsnano.3c08811. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data will be made available on request.












